HKD 11.25
−3.60%Oct 30, 2026, 02:30 UTC
InnoCare Pharma announced that its TL1A and IL-23p19 bispecific antibody ICP-B161 completed enrollment of its first participant in a Phase I clinical trial.
Source:Oct 13, 2026, 00:45 UTC
China’s Center for Drug Evaluation approved a registration Phase III clinical trial of InnoCare’s mesutocalx combined with orelabrutinib for relapsed or refractory marginal zone lymphoma.
Source:Oct 12, 2026, 01:09 UTC
China’s National Medical Products Administration approved clinical trials of InnoCare Pharma’s ICP-B161, a bispecific antibody targeting TL1A and IL-23p19, for inflammatory bowel disease and other autoimmune diseases.
Source:Sep 30, 2026, 10:07 UTC
Sunland BioMed Ltd and its concert parties reduced their combined stake in InnoCare Pharma from 7.23% to 6.94% after Sunland BioMed sold 5 million Hong Kong-listed shares.
Source:Sep 24, 2026, 04:14 UTC
InnoCare Pharma's wholly owned subsidiary Beijing InnoCare Pharma Tech signed a research collaboration and licensing agreement with Eli Lilly to discover and develop up to five innovative target programs, with up to $100 million in upfront and near-term milestone payments and up to about $3.25 billion in potential development and commercialization milestones.
Sep 21, 2026, 03:41 UTC
Innolux subsidiary Raysees Technology (6861) reported commercial shipments of its X-ray inspection systems for DRAM memory and SMT/PCB inspection, and said AI server cold-plate samples from Tier 1 and Tier 2 customers are under testing in Taiwan.
Source:Sep 11, 2026, 07:14 UTC
Innolux Corporation is restructuring its factories, with its second plant scheduled to close in September 2026, prompting subsidiary InnoCare Optoelectronics to prepare for a major supply-chain adjustment.
Source:Sep 9, 2026, 00:49 UTC
Innocare Pharma announced that its self-developed bispecific antibody-drug conjugate ICP-B381 targeting PSMA and STEAP1 received clinical trial approval from China's NMPA CDE for treating solid tumors including prostate cancer, marking the company's first bispecific ADC and third ADC candidate to enter clinical development.
Source:Sep 7, 2026, 08:16 UTC
InnoCare Pharma's wholly-owned subsidiary Beijing InnoCare acquired a 3.5% stake in Guangzhou InnoCare for 238 million yuan through a public listing auction at a property exchange, completing the transaction and business registration, raising its stake to 96.5%.
Source:Aug 24, 2026, 09:32 UTC
InnoCare Pharma announced its first-half 2026 results, reporting a net profit of 246 million yuan, turning from a loss in the same period last year.
Aug 4, 2026, 01:00 UTC
InnoCare announced that its combination of orelabrutinib and mesutoclax was granted breakthrough therapy designation by the Center for Drug Evaluation of the National Medical Products Administration for the treatment of patients with marginal zone lymphoma who have received at least one prior therapy.
Source:Jul 27, 2026, 09:42 UTC
InnoCare Pharma announced that its TYK2 inhibitor fadeucravacitinib (ICP-488) achieved the primary endpoint in a Phase III registrational trial for moderate-to-severe plaque psoriasis.
Source:Jul 20, 2026, 09:38 UTC
Directors Jisong Cui, Renbin Zhao, and Xiangyang Chen of InnoCare Pharma reduced their holdings of the company's A shares through centralized bidding.
Source:Jul 16, 2026, 08:43 UTC
Incyte announced positive Phase 2 results for its drug soficitinib in treating non-segmental vitiligo, meeting the primary endpoint.
Jul 15, 2026, 10:44 UTC
Inncare Bio announced that its phase 3 clinical trial for soficitinib (ICP-332) in treating moderate-to-severe atopic dermatitis met its primary endpoint.
Source:Jul 6, 2026, 01:00 UTC
InnoCare Pharma dosed the first patient in a clinical trial of its novel CDH17 targeted ADC ICP-B208 in China.
Source: